Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 4, 2000, Pages 425-432

  Plein, K ^a,d   Hotz, J ^a   Wurzer, H ^b   Fumagalli, I ^c   Luhmann R ^e   Schneider, A ^e  

^a General Hospital   (Germany)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c Medical Centre   (Switzerland)

^d ALLGEMEINES KRANKENHAUS CELLE   (Germany)

^e NONE

Author keywords

Double blind; Gastro oesophageal reflux disease; GORD; Low dose; Maintenance therapy; Pantoprazole; Proton pump inhibitor; Randomized; Reflux oesophagitis; Relapse

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT;

EID: 0033998133     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012040-00010     Document Type: Article

References (31)

1. 1 Schepp W. Proton pump inhibitory therapy: then and now. Yale J Biol Med 1996; 69:175-186.
2. 2 Tytgat GNJ, Nio CY, Schotborgh RH. Reflux esophagitis. Scand J Gastroenterol Suppl 1990; 175:1-12.
3. 3. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33-118-124.
4. 2-receptor antagonists in the treatment of reflux oesophagitis. Scand J Gastroenterol 1989; 24(suppl 171):136-143.
5. 5 Hegarty JH, Halvorsen L, Hazenberg BP, Nowak A, Smith CL, Thomson AB, et al. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid. Can J Gastroenterol 1997; 11:83-88.
6. 6 Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(suppl B):66B-73B.
7. 7 Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51:460-482.
8. 8 Mössner J, Koop H, Porst H, Wübbolding H, Schneider A, Maier C. One-year prophylactic efficacy and safety of pantoprazole in controlling gastrooesophageal reflux in patients with healed reflux oesophagitis. Aliment Pharmacol Ther 1997; 11:1087-1092.
9. 9 Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798-1810.
10. 10 Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333:1106-1110.
11. 11 Moss SF, Arnold R, Tytgat GNJ, Spechler SJ, Delle Fave G, Rosin D, et al. Consensus statement for management of gastroesophageal reflux disease. J Clin Gastroenterol 1998; 27:6-12.
12. 12 Bardhan KD. The role of proton pump inhibitors in the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(suppl 1):15-25.
13. 13 Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10:529-539.
14. 14 Laursen LS, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol 1995; 30:839-846.
15. 15 Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PW, Hepworth Jones B, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995; 36:492-498.
16. 16 Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107:1305-1311.
17. 17 Klinkenberg Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49:695-710.
18. 18 Johnson DA. Medical therapy of GORD: current state of the art. Hosp Pract 1996; 31:135-148.
19. 19 Ollyo J-B, Monnier P, Fontolliet C, Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993; 3(suppl):3-10.
20. 20 Fennerty MB, Lieberman D. H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease: 'for whom the bell tolls'. Gastroenterology 1994; 107:1545-1548.
21. 21 Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11:365-372.
22. 22 Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:859-867.
23. 23 Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with anti-secretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11:473-482.
24. 24 Savary M, Miller G. The esophagus. In: Handbook and Atlas of Endoscopy. Solothurn, Switzerland: Verlag Gassman AG; 1978. pp. 119-205.
25. 25 Dettmer A, Vogt R, Sielaff F, Lühmann R, Schneider A, Fischer R. Low-dose pantoprazole (20 mg) is effective for relief of symptoms and healing of lesions in mild reflux esophagitis. A randomised, double-blind, parallel and multi-centre study. Aliment Pharmacol Ther 1998; 12:865-872.
26. 26 Green JRB. Is there such an entity as mild oesophagitis? Eur J Clin Res 1993; 4:29-34.
27. 27 Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C, and the European Pantoprazole Study Group. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux esophagitis. Aliment Pharmacol Ther 1999; 13:1481-1491.
28. 28 Lundell L. Long-term treatment of gastro-oesophageal reflux disease with omeprazole. Scand J Gastroenterol Suppl 1994, 201:74-78.
29. 29 Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11:887-897.
30. 30 Mohamed AH, Hunt RH. The rationale of acid suppression in the treatment of acid-related disease. Aliment Pharmacol Ther 1994; 8(suppl 1):3-10.
31. 31 Freston JW, Malagelada JR, Petersen H, McCloy RF. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995; 7:577-586.